Amgen's denosumab becomes first drug to delay bone metastases in cancer
This article was originally published in Scrip
Executive Summary
Amgen's novel drug Xgeva (denosumab) has become the first agent which has been shown in a large trial to delay the development of bone metastases in cancer, after meeting its primary endpoint in a long-awaited Phase III trial in prostate cancer. Amgen revealed top-line data of the study, which showed that denosumab improved median bone metastases-free survival by a median of about four months.